2019
Longitudinal molecular trajectories of diffuse glioma in adults
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 2019, 576: 112-120. PMID: 31748746, PMCID: PMC6897368, DOI: 10.1038/s41586-019-1775-1.Peer-Reviewed Original ResearchConceptsAdult patientsDiffuse gliomasRecurrent gliomaOverall survivalPoor outcomeCurrent therapiesChromosome arms 1p/19qAcquired alterationsMajor subtypesTherapeutic resistanceGliomasGlioma developmentGene alterationsIDH mutationsGlioma subtypesPatientsHypermutator phenotypeDriver genesSubtypesClinical annotationSurvivalSubclonal selectionCell cycleAlterationsLittle evidence
2015
Survival and low-grade glioma: the emergence of genetic information.
Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M. Survival and low-grade glioma: the emergence of genetic information. Neurosurgical FOCUS 2015, 38: e6. PMID: 25552286, PMCID: PMC4361022, DOI: 10.3171/2014.10.focus12367.Peer-Reviewed Original ResearchConceptsLow-grade gliomasHigh-grade gliomasLGG patientsRefining risk stratificationEnd Results ProgramUniformly fatal diseaseRole of tumorNational Cancer InstituteOverall survivalYounger patientsRisk stratificationClinical variablesResults ProgramClinical managementClinical trialsSuch tumorsCurrent treatmentSurvival trendsTumor markersBetter survivalCancer InstitutePatientsFatal diseaseGliomasTumor expression profiles
2014
Local control after fractionated stereotactic radiation therapy for brain metastases
Rajakesari S, Arvold ND, Jimenez RB, Christianson LW, Horvath MC, Claus EB, Golby AJ, Johnson MD, Dunn IF, Lee EQ, Lin NU, Friesen S, Mannarino EG, Wagar M, Hacker FL, Weiss SE, Alexander BM. Local control after fractionated stereotactic radiation therapy for brain metastases. Journal Of Neuro-Oncology 2014, 120: 339-346. PMID: 25059451, DOI: 10.1007/s11060-014-1556-5.Peer-Reviewed Original ResearchConceptsStereotactic radiation therapyBrain metastasesStereotactic radiosurgeryRadiation therapyLocal controlNon-small cell lung cancerCommon tumor histologyDose intensification strategiesLocal control rateMedian tumor diameterCell lung cancerAcute toxicityIntracranial progressionLocal progressionMedian survivalOverall survivalMedian timeTumor diameterTumor histologyCommon symptomsEloquent areasControl rateLung cancerMild headacheBreast cancer